Garcia et al. first identified GPR75 as a receptor for 20-HETE (Garcia et al., 2017) and Cardenas et al. demonstrated that the 20-HETE/GPR75 signaling pathways contributed to metastatic prostate cancer progression (Cárdenas et al., 2019). This evidence concerns the gene GPR75 and metastatic prostate carcinoma.